Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma

Kelkar, Amar H.; Cliff, Edward R. Scheffer; Jacobson, Caron A.; Abel, Gregory A.; Dijk, Stijntje W.; Krijkamp, Eline M.; Redd, Robert; Zurko, Joanna C.; Hamadani, Mehdi; Hunink, M.G. Myriam; Cutler, Corey

doi:10.7326/m22-2276

Cited by 7 publications

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, at the time of analysis, fewer SOC options were available to R/R DLBCL patients. A later study did not find second-line CAR T-cell therapy to be cost-effective in DLBCL patients ( 88 ) at a willingness-to-pay threshold of $200,000/QALY. However, two other cost analyses did find CAR T-cell therapy to be cost-effective in the second-line setting ( 89 , 90 ) at a willingness-to-pay threshold of $150,000 in both studies as these studies took into account less effective and newer but more expensive and indefinite salvage treatment options.…”

Section: Car T-cell Toxicitiesmentioning

confidence: 96%

Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

Hu,

Korsos,

Palomba

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Section: Car T-cell Toxicitiesmentioning

confidence: 96%

Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

Hu,

Korsos,

Palomba

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…422 Furthermore, cell therapy often results in high costs, limiting its widespread adoption and accessibility. 423 Safety issues also pose significant challenges for cell therapy, including the risk of potential immune reactions. 424 For example, even the use of a patient’s own cells for treatment can trigger unpredictable immune responses.…”

Section: Hydrogels For Cell Therapymentioning

confidence: 99%

Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions

Lu,

Ruan,

Huang

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

The applications of hydrogels have expanded significantly due to their versatile, highly tunable properties and breakthroughs in biomaterial technologies. In this review, we cover the major achievements and the potential of hydrogels in therapeutic applications, focusing primarily on two areas: emerging cell-based therapies and promising non-cell therapeutic modalities. Within the context of cell therapy, we discuss the capacity of hydrogels to overcome the existing translational challenges faced by mainstream cell therapy paradigms, provide a detailed discussion on the advantages and principal design considerations of hydrogels for boosting the efficacy of cell therapy, as well as list specific examples of their applications in different disease scenarios. We then explore the potential of hydrogels in drug delivery, physical intervention therapies, and other non-cell therapeutic areas (e.g., bioadhesives, artificial tissues, and biosensors), emphasizing their utility beyond mere delivery vehicles. Additionally, we complement our discussion on the latest progress and challenges in the clinical application of hydrogels and outline future research directions, particularly in terms of integration with advanced biomanufacturing technologies. This review aims to present a comprehensive view and critical insights into the design and selection of hydrogels for both cell therapy and non-cell therapies, tailored to meet the therapeutic requirements of diverse diseases and situations.

show abstract